

**Efficacy and safety of combination therapy with low dose rivaroxaban in patients with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials**


Tommaso Bucci, Francesco Del Sole, Danilo Menichelli, Gioacchino Galardo, Flavio Giuseppe Biccirè,  
Alessio Farcomeni, Gregory Y.H. Lip, Pasquale Pignatelli, Daniele Pastori

Supplementary materials


**Supplementary Table S1.** Literature online search strategies.

Database	Search strategy
PubMed	‘rivaroxaban’ AND ‘coronary artery disease’ OR ‘peripheral artery disease’
Embase	' rivaroxaban' /exp AND ‘coronary artery disease’ OR ‘peripheral artery disease’ /exp
Web of Science	ALL= rivaroxaban ' AND ALL= ‘coronary artery disease’ OR ‘peripheral artery disease’


Supplementary Figure S1. Funnel plots for safety endpoints.




Supplementary Figure S2. Funnel plots for efficacy endpoints.



**Supplementary Figure S3. Efficacy endpoints in patients with coronary artery disease.**




**Supplementary Figure S4. Safety endpoints in patients with coronary artery disease.**




**Supplementary Figure S5. Safety and efficacy endpoints in patients with peripheral artery disease.**


### Cardiovascular events




### Cardiovascular death




### Stroke



### All-cause mortality



### Myocardial Infarction



### Major bleeding

